Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

PCNA inhibitor AOH1996

An orally bioavailable, small molecule inhibitor of proliferating cell nuclear antigen (PCNA), with potential chemo-sensitizing and antineoplastic activities. Upon oral administration, PCNA inhibitor AOH1996 penetrates cells and targets and binds to PCNA, preventing the binding of PCNA's interacting proteins to PCNA. This disrupts the interactions between PCNA and these proteins and may result in DNA replication stress and inhibition of DNA repair, which may enhance the efficacy of some antineoplastic agents and induce apoptosis. PCNA is a scaffold protein involved in multiple cellular processes via its interactions with many proteins.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:proliferating cell nuclear antigen inhibitor AOH1996
Code name:AOH 1996
AOH1996
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search